shows the cube propagation in the coronal direction and DVF of the inserts. Mean S-I distance are 0.16±0.14cm for cube and 0.27±0.12cm for sphere. DVF have a mean magnitude scale of 0.00-1.11cm for the 4DCT. The mean transition has same dimension, according to the space covered by the objects during phases bin. The motion direction is obtained by reverse mode, otherwise uncorrected track is provided by the DVF module. Graph (Figure1b) shows the displacement of 2 ROIs in S-I directions per phases. A strong correlation (R 2 =0.95) with position, time and direction of the inserts (cube and sphere) is obtained (Figure 1c) .
Purpose/Objective: IMRT is an established treatment option for patients with prostate cancer, as it allows the delivery of highly conformal doses to the target whilst lowering doses to OARs. In many centres, including ours, the provision of static field IMRT has been supplanted by VMAT which offers faster treatment times and greater monitor unit efficiency. The results of published dosimetric comparisons between IMRT and VMAT for prostate cancer have varied, typically with small sample sizes. Here we present a retrospective dosimetric audit of clinical IMRT and VMAT treatment plans for prostate cancer with a large sample size (N = 1344). Materials and Methods: Our standard prostate treatment is a three dose level integrated simultaneous-boost technique based on the CHHiP trial, with a prescription dose of 60Gy in 20 fractions, delivery of which has moved from five-field step-and-shoot IMRT to predominantly single arc VMAT using Elekta linear accelerators. Planning is performed using the Philips Pinnacle TPS. Automatically populated dosimetric summary forms (AutoForms) are routinely generated at our centre for the purposes of optimisation and reporting. Prostate AutoForms were collected and cross-referenced with treatment planning system PDF reports to determine which patients were treated with IMRT or VMAT. Patients with artificial hip replacements were excluded as we do not treat these patients with VMAT. All data collection was fully automated. Target, rectum and bladder dosimetric statistics were compared using histograms and Mann-Whitney U tests, with a significance level of 0.01. It should be noted that our standard VMAT inverse optimisation class solution is slightly different to the IMRT version. However, all plans have been individually optimised by suitably trained individuals. Results: The volume of rectum receiving 41% of the prescription dose or greater, V41%, and V88% were significantly lower for VMAT than IMRT. However, V68% and V95% were significantly higher. Bladder dose statistics (V68%, V81% and V100%) were lower for VMAT but the differences were not significant. The percentage of the prescription dose covering 99% of each target volume, D99%, was significantly higher for VMAT than for IMRT. Sharp cut-offs at tolerance values were much more pronounced in the histograms for IMRT than for VMAT, supporting anecdotal evidence that coverage tolerances are more easily achieved using VMAT. Heterogeneity, defined as the difference between the maximum and minimum percentage dose to 1cc of the target volume, was significantly lower for VMAT than IMRT. Conclusions: We have performed a large dosimetric audit, comparing IMRT and VMAT for prostate cancer. Bladder dose statistics are not significantly different. Some rectum dose statistics are significantly greater for VMAT and others for IMRT. However, VMAT shows a clear advantage over IMRT in coverage statistics. Most strikingly of all, the dose to the target volume was much more homogeneous for VMAT than for IMRT. 
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